Drugs like enzalutamide that inhibit male hormones from activating the androgen receptor have been used to treat advanced prostate cancer for more than a decade. While successful in most cases, these drugs can eventually stop working, but there is a limited understanding about how this change occurs.
|
For decades, researchers at the University of Michigan Rogel Cancer Center have been searching for ways to fundamentally change the approach to treating laryngeal cancer and underlying assumptions to improve clinical care for patients. Laryngeal cancer can severely alter patients’ ability to talk and breathe. Treatment is limited, relying on aggressive surgery and insufficient therapeutics, which leaves patients with few options.
|
Patients with relapsed multiple myeloma are resistant to commonly used treatments. Researchers are one step closer to understanding the genetic reason why.
|
Within a pancreatic cancer tumor, different cell types interact to facilitate the tumor’s growth. Researchers see disrupting this metabolic crosstalk as a compelling target for treatment.
|
Friends, faculty and staff of the Rogel Cancer Center gathered amidst a rainbow of lights, ribbons and balloons on Sept. 23 to raise money for cancer research.
|
|
|
|
|
|
|
|
|
MENU